Sanofi Reports Deal with US Government to Lower Medicine Costs

MT Newswires Live12-20

Sanofi (SNY) said Friday it has reached an agreement with the US government to lower medicine costs.

Medicaid programs can access certain Sanofi medicines at the same prices available to other high-income nations, cutting prices by an average of 61% for some medicines that treat diabetes, cardiovascular and neurological conditions and cancer, the company said.

Sanofi also said it will offer consumers access to lower-cost medicines via TrumpRx.gov and other direct-to-patient platforms at an average savings of nearly 70% on some medicines to treat infections and cardiovascular and diabetic conditions.

The agreement provides a three-year period free from Section 232 tariffs on products imported by Sanofi, it added.

Sanofi also said the deal does not impact its Take the Lead growth strategy or financial outlook during the agreement period.

Price: 48.36, Change: +0.37, Percent Change: +0.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment